Accelerate past the financial hurdles of discovery

When we see the potential in your business, we consider sharing in the financial risk to make that potential a reality.

We see today’s drug discovery industry evolution. And, whether it’s a company incubator strategy or other innovative financial partnership, we embrace collaborations that drive discovery. Let’s talk about how we can reduce your need for upfront capital like we’ve successfully done for

FemtaFemta Pharmaceuticals is fast-follower/bio-better company focused on the development of therapeutic monoclonal antibodies for the treatment of various disease states in the areas of inflammation, autoimmune disease and oncology.

,

VivaMab,VivaMab LLC is a biopharmaceutical company developing a portfolio of bio-better protein therapeutics products for a broad range of therapeutic areas.

Inhibrx.InhibRx is taking an innovative approach to developing a portfolio of proprietary therapeutic antibody products against highly validated disease targets with large unmet medical needs by leveraging a small but highly experienced management and scientific team across a large portfolio of antibody projects and utilizing a strategic partner network of top quality service providers.

Our focus on delivering cost-effective services extends to more traditional project-by-project relationships, too. Find the solution that fits your budget with our gold and silver pricing packages. And pay for only what you need, as we pinpoint and deliver on a highly specific requirement within your discovery process. Financial partnerships are rapidly replacing the traditional drug discovery business models that are simply no longer sustainable – and BioAtla is leading the way. So whether you are looking for a simple services-for-fee arrangement or a custom multi-year program, we have the experience and compensation option for you. That’s the BioAcceleration™ difference.

Put our flexible collaborative strategy to work for you. Learn more by calling 858-558-0708 ext. 0 or send us an email.